• search
CDMO Services in United Kingdom CDMO Services in United Kingdom

CDMO Services in United Kingdom

Our API, PEGylation agent and chemical intermediate CDMO plant in Mirfield, United Kingdom is audited by US FDA, UK MHRA, KMFDS and BSI. The facility is capable of supporting drug development and commercial manufacturing.   

Manufacturing Capability at Mirfield, United Kingdom includes: Large Scale (up to 2,000 L) manufacturing suite with ISO 8 (grade D) loading and packaging areas 2500L glass lined reactors and a 1500L Hastelloy filter drier 2 x 9000 liter GLMS reactors with distillation capability 1 x 3000 liter agitated Nutsche type SS pressure filter Clean room manufacturing suite for medium scale GMP chemistry (1 - 200L) Hastelloy hydrogenation or pressure reaction to 20 bar and stainless-steel Filter Drier 100L capacity 3 Bar

Contact Us

Chemical intermediate manufacturing plant in Mirfield, United Kingdom

Why Aurigene Services?

18 years of experience

Experience gained from 100+ discovery programmes

World-class infrastructure

Track record of delivering 8+ IND candidates

Flexible working models

Quick turnaround time

Capabilities to apply multiple modalities

Seamless integration capabilities with Biology as well as CDMO services

Integrated project management

Expertise in various therapeutic modalities


Aurigene Pharmaceutical Services Limited is a leading contract research, development and manufacturing organization (CDMO) providing end-to-end solutions. With a strong legacy of services in discovery, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide.

Small Molecules Development and manufacturing facility
Why meet us at CPHI Barcelona?

SEPTEMBER 04, 2023

Why meet us at CPHI Barcelona?

Discover the Opportunities: Visit Aurigene Pharmaceutical Services at CPHI BarcelonaThe Contract Research, Development and Manufacturing Organization (CRDMO) industry is a dynamic and rapidly evolving sector emerging as it plays a vital role in providing a wide range of services enabling drug companies to bring their products to market efficiently and effectively...

Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role in enabli...

Read More
Anti-Infective Drug Discovery

Anti-Infective Drug Discovery

Objective & Challenges: Objective was to identify an optimized anti-bacterial lead molecule with in vivo efficacy in relevant infection models an acceptable safety profile, and a patentable series.      Challenge was to develop a more efficacious compound than the reference standard.Study design: Compounds were designed and synth...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug


Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.